On November 19, 2025, CANbridge Pharmaceuticals Inc. (Stock Code: 1228) released a circular detailing plans to hold an Extraordinary General Meeting (EGM) virtually on December 4, 2025, at 9:00 a.m. The principal purpose is to seek shareholder approval for a proposed refreshment of the existing general mandate, which was fully utilized through share issuances in August and September 2025.

According to the announcement, the refreshed mandate would allow directors to allot and issue new shares not exceeding 20% of the issued share capital of the company as of the meeting date (excluding any shares held in treasury). The announcement specifies that this authority, if granted, would remain effective until the conclusion of the next annual general meeting or the expiration of the relevant period under prevailing regulations.

Shareholders who wish to participate in the virtual EGM can log in online on the specified date. The announcement also provides instructions on submitting proxy forms, along with technical details regarding electronic participation. The company notes that only registered shareholders or their proxy representatives will be eligible to vote.